期刊文献+

应用蒙特卡罗模拟对铜绿假单胞菌感染的抗菌药物方案评价 被引量:8

Use of Monte Carlo simulation method to optimize dosing regimen of six kinds of antimicrobial agents in patients infected with P.aeruginosa
原文传递
导出
摘要 目的:根据药动/药效(PK/PD)理论应用蒙特卡罗模拟进行6种抗菌药物对铜绿假单胞菌给药方案的评价。方法:将左氧氟沙星、环丙沙星、头孢吡肟、头孢他啶、哌拉西林/他唑巴坦和亚胺培南/西司他丁各给药方案对铜绿假单胞菌进行5 000次蒙特卡罗模拟,通过获得的累积反应分数(CFR)对给药方案的治疗效果进行比较。结果:左氧氟沙星(0.5 g qd)的CFR为27.55%;环丙沙星(0.4 g qd)的CFR分别为79.33%;头孢吡肟4种给药方案(1 g bid,1 g tid,2 g bid和2 g tid)的CFR分别为56.14%,70.51%,69.18%和82.77%;头孢他啶4种给药方案(1 g bid,1 g tid,2 g bid和2 g tid)的CFR分别为18.02%,40.71%,31.15%和71.17%;哌拉西林/他唑巴坦2种给药方案(4.5 g tid和4.5 g q6h)的CFR分别为33.66%和56.31%;亚胺培南/西司他丁2种给药方案(1 g tid和1 g q6h)的CFR分别为为67.75%和73.58%。结论:6种抗菌药物临床常规单药治疗耐药情况严重,因此当铜绿假单胞菌感染时需考虑联合用药。 Objective: To estimate the dosage regimens of six kinds of antimicrobial agents for pseudomonas aeruginosa utilizing Monte Carlo simulation (MCS) based on PK/PD. Methods: A 5 000-subject Monte Carlo simulation was conducted to determine the cumulative fraction of response (CFR) for levofloxacin, ciprofloxacin, cefepime, ceftazidime, piperacillin/tazobactam and imipenem-cilastatin against Pseudomonas aeruginosa. Results: The CFRs were 27.55% for levofloxacin (0.5 g qd); 79.33% for ciprofloxacin (0.4 g qd) ; 56.14% , 70.51%, 69.18% and 82.77% for four dosage regimens of cefepime (1 g bid, 1 g tid, 2 g bid and 2 g tid) ; 18.02% , 40.71% , 31.15% and 71.17% for four dosage regimens of ceftazidime (1 g bid, 1 g tid, 2 g bid and 2 g tid) ; 33.66% and 56.31% for piperacillin/tazobactam (4.5 g tid and 4.5 g q6h) ; 67.75% and 73.58% for imipenem-cilastatin (1 g tid and 1 g q6h). Conclusion: The dosage regimen of six kinds of antibacterial drugs for pseudomonas aeruginosa has not been optimized, so the drug monas aerueinosa infection. combination should be considered for the treatment of pseudo-monas aeruginosa infection.
出处 《中国新药杂志》 CAS CSCD 北大核心 2014年第23期2817-2821,2826,共6页 Chinese Journal of New Drugs
基金 辽宁省教育厅2010年立项课题(L2010578)
关键词 蒙特卡罗模拟 左氧氟沙星 环丙沙星 头孢吡肟 头孢他啶 哌拉西林/他唑巴坦 亚胺培南/西司他丁 铜绿假单胞菌 Monte Carlo simulation levofloxaein ciprofloxacin cefepime ceftazidime piperacillin/tazobactam impenem-cilastatin pseudomonas aeruginosa
  • 相关文献

参考文献8

二级参考文献90

共引文献85

同被引文献59

  • 1Dagan R, Klugman KP, Craig WA, et al. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy[J]. J Antimocrob Chemother, 2001, 47(2): 129-140. 被引量:1
  • 2Cazzola M, Di Pema F, Boveri B, et al. Interrelationship between the pharmacokinetics and pharmacodynamics of cefaclor advanced formulation in patients with acute exacerbation of chronic bronchitis[J]. J Chemother, 2000, 12(3): 216-222. 被引量:1
  • 3Drusano GL.Pharmacokinetics and pharmacodynamics of antimicrobials[J].Clin Infect Dis,2007,45(Suppl 1):S89-S95. 被引量:1
  • 4Kozawa O,Uematsu T,Matsuno H,et al.Pharmacokinetics and safety of a new parenteral carbapenem antibiotic,biapenem(L-627),in elderly subjects[J].Antimicrob Agents Chemother,1998,42(6):1433-1436. 被引量:1
  • 5Frei CR,Wiederhold NP,Burgess DS.Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation[J].J Antimicrob Chemother,2008,61(3):621-628. 被引量:1
  • 6Perry CM,Ibbotson T.Biapenem[J].Drugs,2002,62(15):2221-2234. 被引量:1
  • 7Roberts JA,Lipman J.Pharmacokinetic issues for antibiotics in the critically ill patient[J].Crit Care Med,2009,37(3):840-851. 被引量:1
  • 8Jaruratanasirikul S,Wongpoowarak W,Jullangkoon M,et al.Population pharmacokinetics and dosing simulations of imipenem in serious bacteraemia in immunocompromised patients with febrile neutropenia[J].J Pharmacol Sci,2015,127(2):164-169. 被引量:1
  • 9张传军,鲁惠敏.依替米星与阿米卡星临床疗效及安全性比较[J].医药论坛杂志,2008,29(2):4-6. 被引量:9
  • 10周东升,林荣,沈志君,唐吉斌,潘晓龙.耐碳青霉烯鲍曼不动杆菌分子流行病学研究[J].安徽医药,2011,15(2):181-183. 被引量:4

引证文献8

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部